Skip to main content

We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.news

SubscribeLogin
Published • loading... • Updated

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Summary by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported second-quarter 2026 revenue of $214 million, led by growth across its commercial rare-disease portfolio, while the company prepared for potential regulatory decisions on two gene therapies and a late-stage data readout in Angelman syndrome. Chief Exe

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call August 4, 2026 5:00 PM EDTCompany ParticipantsJoshua Higa - Director of Investor Relations &...

·Ra'anana, Israel
Read Full Article
MarketBeatMarketBeat
Center

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported second-quarter 2026 revenue of $214 million, led by growth across its commercial rare-disease portfolio, while the company prepared for potential regulatory decisions on two gene therapies and a late-stage data readout in Angelman syndrome. Chief Exe

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Wednesday, August 5, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Novato icon

Novato

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal